01/21/2023
This past June, the US Food and Drug Administration approved semaglutide, a glucagon-like peptide 1 receptor agonist marketed as Wegovy, for chronic weight management based on results from the four 68-week STEP (Semaglutide Treatment Effect in People with obesity) trials. Now, the findings from a...